**WHAT IS CLAIMED IS:**

1. Use of an effective amount of Compound (A), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a cancer in a subject, wherein:

Compound (A) is , or a pharmaceutically acceptable salt thereof;

wherein the cancer is selected from a colorectal cancer, a pancreatic cancer and a non-small cell lung cancer; and

wherein the subject has a mutation selected from the group consisting of a TP53 and a KRAS mutation.

2. The use of Claim 1, wherein the cancer is a colorectal cancer.

3. Use of a combination of compounds in the manufacture of a medicament for the treatment of a cancer in a subject, wherein the combination includes an effective amount of Compound (A), or a pharmaceutically acceptable salt thereof, and an effective amount of a KRAS inhibitor, or a pharmaceutically acceptable salt thereof, wherein:

Compound (A) is , or a pharmaceutically acceptable salt thereof;

wherein the cancer is selected from a colorectal cancer, a pancreatic cancer and a non-small cell lung cancer;

wherein the subject has a mutation selected from the group consisting of a TP53 and a KRAS mutation; and

wherein the KRAS inhibitor is selected from the group consisting of sotorasib and MRTX849, or a pharmaceutically acceptable salt of any of the foregoing.

4. The use of Claim 3, wherein the KRAS inhibitor is sotorasib.

5. The use of Claim 3, wherein the KRAS inhibitor is MRTX849.

6. The use of any one of Claims 1-5, wherein the mutation is a KRAS mutation.

7. The use of any one of Claims 1-5, wherein the mutation is a TP53 mutation.

8. The use of any one of Claims 1-5, wherein the mutation is a TP53 and KRAS mutation.

9. The use of any one of Claims 2-8, wherein the cancer is a colorectal cancer.

10. The use of any one of Claims 2-8, wherein the cancer is a pancreatic cancer.

11. The use of any one of Claims 2-8, wherein the cancer is a non-small cell lung cancer.